The enduring centrality of dopamine in the pathophysiology of schizophrenia. In vivo evidence from the prodrome to the first psychotic episode.

Advances in Pharmacology

Volumn 68, Issue , 2013, Pages 199-220

  Bonoldi, Ilaria ^a,b,c   Howes, O D ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cause; Dopamine; Etiology; Onset; Pathophysiology; Prodrome; Psychosis; Schizophrenia

Indexed keywords

AMPHETAMINE; CHLORPROMAZINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE C 11; DOPAMINE F 18; DOPAMINE TRANSPORTER; IODOBENZAMIDE I 123; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

AKATHISIA; AKINESIA; ANTERIOR CINGULATE; ARTICLE; CEREBROSPINAL FLUID; CONCEPTUAL FRAMEWORK; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; FRONTAL CORTEX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFERIOR FRONTAL GYRUS; MOLECULAR IMAGING; MOOD DISORDER; NEGATIVE SYNDROME; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; PHENOMENOLOGY; POPULATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RIGIDITY; RISK FACTOR; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOMATOLOGY; SYNAPTOSOME;

CAUSE; DOPAMINE; ETIOLOGY; ONSET; PATHOPHYSIOLOGY; PRODROME; PSYCHOSIS; SCHIZOPHRENIA;

ANIMALS; DOPAMINE; HUMANS; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84884325284     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411512-5.00010-5     Document Type: Chapter

References (122)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. The American Journal of Psychiatry 1998, 155:761-767.
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:8104-8109.
3. Abi-Dargham A., van de Giessen E., Slifstein M., Kegeles L.S., Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biological Psychiatry 2009, 65:1091-1093.
4. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. The American Journal of Psychiatry 1999, 156:1646-1649.
5. Allen P., Luigjes J., Howes O.D., Egerton A., Hirao K., Valli I., et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophrenia Bulletin 2012, 38:1268-1276.
6. an der Heiden W., Hafner H. The epidemiology of onset and course of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2000, 250:292-303.
7. Andreasen N.C., Arndt S., Alliger R., Miller D., Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Archives of General Psychiatry 1995, 52:341-351.
8. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, (4th ed., text rev.). Washington, DC: Author.
9. Arndt S., Andreasen N.C., Flaum M., Miller D., Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Archives of General Psychiatry 1995, 52:352-360.
10. Barch D.M. Neuropsychological abnormalities in schizophrenia and major mood disorders: Similarities and differences. Current Psychiatry Reports 2009, 11:313-319.
11. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?. Brain Research. Brain Research Reviews 1998, 28:309-369.
12. Bleuler E. Dementia praecox or the group of schizophrenias 1950, International Universities Press, New York.
13. Bloemen O.J., de Koning M.B., Gleich T., Meijer J., de Haan L., Linszen D.H., et al. Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at ultra high risk for psychosis. European Neuropsychopharmacology 2013, 23:126-132.
14. Boksa P. Animal models of obstetric complications in relation to schizophrenia. Brain Research. Brain Research Reviews 2004, 45:1-17.
15. Boksa P., El-Khodor B.F. Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: Possible implications for schizophrenia and other disorders. Neuroscience and Biobehavioral Reviews 2003, 27:91-101.
16. 18F] fluorodopa PET imaging. Schizophrenia Research 2008, 106:148-155.
17. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2569-2574.
18. Broome M.R., Fusar-Poli P., Matthiasson P., Woolley J.B., Valmaggia L., Johns L.C., et al. Neural correlates of visuospatial working memory in the 'at-risk mental state'. Psychological Medicine 2010, 40:1987-1999.
19. Broome M.R., Matthiasson P., Fusar-Poli P., Woolley J., Johns L., Tabraham P., et al. Neural correlates of executive function and working memory in the 'at-risk mental state'. The British Journal of Psychiatry 2009, 194:25-33.
20. Callicott J.H., Mattay V.S., Verchinski B.A., Marenco S., Egan M.F., Weinberger D.R. Complexity of prefrontal cortical dysfunction in schizophrenia: More than up or down. The American Journal of Psychiatry 2003, 160:2209-2215.
21. Cantor-Graae E. The contribution of social factors to the development of schizophrenia: A review of recent findings. Canadian Journal of Psychiatry 2007, 52:277-286.
22. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacologica et Toxicologica 1963, 20:140-144.
23. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180:1200.
24. Chen K.C., Yang Y.K., Howes O., Lee I.H., Landau S., Yeh T.L., et al. Striatal dopamine transporter availability in drug-naive patients with schizophrenia: A case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis. Schizophrenia Bulletin 2013, 39:378-386.
25. Creese I., Burt D., Snyder S. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
26. Crossley N.A., Mechelli A., Fusar-Poli P., Broome M.R., Matthiasson P., Johns L.C., et al. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Human Brain Mapping 2009, 30:4129-4137.
27. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: A review and reconceptualization. The American Journal of Psychiatry 1991, 148:1474-1486.
28. 1H-MRS imaging study. The International Journal of Neuropsychopharmacology 2013, 16:471-475.
29. Demjaha A., Murray R.M., McGuire P.K., Kapur S., Howes O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. The American Journal of Psychiatry 2012, 169:1203-1210.
30. Egerton A., Chaddock C.A., Winton-Brown T.T., Bloomfield M.A., Bhattacharyya S., Allen P., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: Findings in a second cohort. Biological Psychiatry 2013, 74:106-112.
31. Farde L., Wiesel F.A., Nordstrom A.L., Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 1989, 99(Suppl.):S28-S31.
32. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M., Barale F., et al. Predicting psychosis: A meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry 2012, 69:1-10.
33. Fusar-Poli P., Deste G., Smieskova R., Barlati S., Yung A.R., Howes O., et al. Cognitive functioning in prodromal psychosis: A meta-analysis. Archives of General Psychiatry 2012, 69:562-571.
34. Fusar-Poli P., Howes O.D., Allen P., Broome M., Valli I., Asselin M.C., et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: A multimodal imaging study. Archives of General Psychiatry 2010, 67:683-691.
35. Fusar-Poli P., Howes O.D., Allen P., Broome M., Valli I., Asselin M.C., et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Molecular Psychiatry 2011, 16:67-75.
36. Fusar-Poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part I: Meta-analysis of dopamine active transporter (DAT) density. Schizophrenia Bulletin 2013, 39:22-32.
37. Fusar-Poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: Meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophrenia Bulletin 2013, 39:33-42.
38. Fusar-Poli P., Stone J.M., Broome M.R., Valli I., Mechelli A., McLean M.A., et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Archives of General Psychiatry 2011, 68:881-890.
39. Fusar-Poli, P., Bechdolf, A., Taylor, M., Bonoldi, I., Carpenter, W., Yung, A., et al. (in press). At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk. Schizophrenia Bulletin, 39, 923-932.
40. Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., et al. (in press). The psychosis high risk state: A comprehensive state of the art review. Archives of General Psychiatry, 70, 107-120.
41. Glahn D.C., Ragland J.D., Abramoff A., Barrett J., Laird A.R., Bearden C.E., et al. Beyond hypofrontality: A quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Human Brain Mapping 2005, 25:60-69.
42. Hall H., Sedvall G., Magnusson O., Kopp J., Halldin C., Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994, 11:245-256.
43. Hall F.S., Wilkinson L.S., Humby T., Inglis W., Kendall D.A., Marsden C.A., et al. Isolation rearing in rats: Pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacology, Biochemistry, and Behavior 1998, 59:859-872.
44. Hall F.S., Wilkinson L.S., Humby T., Robbins T.W. Maternal deprivation of neonatal rats produces enduring changes in dopamine function. Synapse 1999, 32:37-43.
45. Heinz A., Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: Salience attribution revisited. Schizophrenia Bulletin 2010, 36:472-485.
46. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophrenia Research 1999, 35:41-50.
47. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995, 346:1130-1131.
48. Hirvonen J., van Erp T.G., Huttunen J., Aalto S., Nagren K., Huttunen M., et al. Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Archives of General Psychiatry 2005, 62:371-378.
49. Howes O., Bose S., Turkheimer F., Valli I., Egerton A., Stahl D., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study. Molecular Psychiatry 2011, 16:885-886.
50. 18F]-DOPA PET imaging study. The American Journal of Psychiatry 2011, 168:1311-1317.
51. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Archives of General Psychiatry 2012, 69:776-786.
52. Howes O., Kapur S. The dopamine hypothesis of schizophrenia: Version III - The final common pathway. Schizophrenia Bulletin 2009, 35:549-562.
53. Howes O.D., Montgomery A.J., Asselin M., Murray R., Grasby P., McGuire P. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. The British Journal of Psychiatry 2007, s51:s13-s18.
54. Howes O., Montgomery A., Asselin M., Valli I., Tabraham P., Johns L., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of General Psychiatry 2009, 66:13-20.
55. 18F]-DOPA imaging study in healthy individuals with auditory hallucinations. Schizophrenia Bulletin 2012, 39:807-814.
56. Huber G., Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Progressi in Medicina 1989, 80:646-652.
57. Huttunen J., Heinimaa M., Svirskis T., Nyman M., Kajander J., Forsback S., et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biological Psychiatry 2008, 63:114-117.
58. Jaspers K. General psychopathology 1959/1963, The John Hopkins University Press, London, (tr. Hoenig, J & Hamilton, M).
59. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. The American Journal of Psychiatry 1991, 148:1301-1308.
60. Juckel G., Schlagenhauf F., Koslowski M., Filonov D., Wustenberg T., Villringer A., et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 2006, 187:222-228.
61. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. The American Journal of Psychiatry 2003, 160:13-23.
62. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 2005, 79:59-68.
63. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. The American Journal of Psychiatry 1999, 156:286-293.
64. Kegeles L.S., Abi-Dargham A., Frankle W.G., Gil R., Cooper T.B., Slifstein M., et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Archives of General Psychiatry 2010, 67:231-239.
65. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
66. Klosterkotter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Archives of General Psychiatry 2001, 58:158-164.
67. Klosterkotter J., Schultze-Lutter F., Ruhrmann S. Kraepelin and psychotic prodromal conditions. European Archives of Psychiatry and Clinical Neuroscience 2008, 258(Suppl. 2):74-84.
68. Kumakura Y., Cumming P. PET studies of cerebral levodopa metabolism: A review of clinical findings and modeling approaches. The Neuroscientist 2009, 15:635-650.
69. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biological Psychiatry 1999, 46:56-72.
70. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:9235-9240.
71. Laruelle M., Abi-Dargham A., van Dyck C., Gil R., D'Souza D.C., Krystal J., et al. Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [(123)I]beta-CIT. Biological Psychiatry 2000, 47:371-379.
72. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001, 12:2971-2974.
73. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987, 91:415-433.
74. Lieberman J.A., Kinon B.J., Loebel A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophrenia Bulletin 1990, 16:97-110.
75. 11C) DOPA and PET. Biological Psychiatry 1999, 46:681-688.
76. Lisman J.E., Grace A.A. The hippocampal-VTA loop: Controlling the entry of information into long-term memory. Neuron 2005, 46:703-713.
77. Lodge D.J., Grace A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. Journal of Neuroscience 2007, 27:11424-11430.
78. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends in Pharmacological Sciences 2011, 32:507-513.
79. Lyon G.J., Abi-Dargham A., Moore H., Lieberman J.A., Javitch J.A., Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophrenia Bulletin 2011, 37:108-117.
80. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. The American Journal of Psychiatry 2001, 158:314-316.
81. Martin-Soelch C., Leenders K.L., Chevalley A.F., Missimer J., Kunig G., Magyar S., et al. Reward mechanisms in the brain and their role in dependence: Evidence from neurophysiological and neuroimaging studies. Brain Research. Brain Research Reviews 2001, 36:139-149.
82. 18F]fluorodopa study. Archives of General Psychiatry 2004, 61:134-142.
83. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience 2002, 5:267-271.
84. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Cannon T., Ventura J., et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: Predictive validity, interrater reliability, and training to reliability. Schizophrenia Bulletin 2003, 29:703-715.
85. Mizrahi R., Addington J., Rusjan P.M., Suridjan I., Ng A., Boileau I., et al. Increased stress-induced dopamine release in psychosis. Biological Psychiatry 2012, 71:561-567.
86. 18F-DOPA PET study. Brain Research 2003, 982:137-145.
87. Morgan D., Grant K.A., Gage H.D., Mach R.H., Kaplan J.R., Prioleau O., et al. Social dominance in monkeys: Dopamine D2 receptors and cocaine self-administration. Nature Neuroscience 2002, 5:169-174.
88. Nelson B., Yuen K., Yung A.R. Ultra high risk (UHR) for psychosis criteria: Are there different levels of risk for transition to psychosis?. Schizophrenia Research 2011, 125:62-68.
89. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. The American Journal of Psychiatry 1995, 152:1444-1449.
90. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 1999, 33:523-533.
91. Pantelis C., Velakoulis D., McGorry P.D., Wood S.J., Suckling J., Phillips L.J., et al. Neuroanatomical abnormalities before and after onset of psychosis: A cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
92. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nature Medicine 2007, 13:1102-1107.
93. Perala J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsa E., Pirkola S., et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry 2007, 64:19-28.
94. Piccini P.P. Dopamine transporter: Basic aspects and neuroimaging. Movement Disorders 2003, 18(Suppl. 7):S3-S8.
95. Pilowsky L.S., Bressan R.A., Stone J.M., Erlandsson K., Mulligan R.S., Krystal J.H., et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Molecular Psychiatry 2006, 11:118-119.
96. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980, 286:74-76.
97. Ragland J.D., Yoon J., Minzenberg M.J., Carter C.S. Neuroimaging of cognitive disability in schizophrenia: Search for a pathophysiological mechanism. International Review of Psychiatry 2007, 19:417-427.
98. Robbins T.W., Everitt B.J. Neurobehavioural mechanisms of reward and motivation. Current Opinion in Neurobiology 1996, 6:228-236.
99. Roiser J.P., Stephan K.E., den Ouden H.E., Barnes T.R., Friston K.J., Joyce E.M. Do patients with schizophrenia exhibit aberrant salience?. Psychological Medicine 2009, 39:199-209.
100. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Medicine 2005, 2:e141.
101. Schobel S.A., Chaudhury N.H., Khan U.A., Paniagua B., Styner M.A., Asllani I., et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013, 78:81-93.
102. Schultz W. Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
103. Schultz W., Dayan P., Montague P.R. A neural substrate of prediction and reward. Science 1997, 275:1593-1599.
104. Schwartz T.L., Sachdeva S., Stahl S.M. Glutamate neurocircuitry: Theoretical underpinnings in schizophrenia. Frontiers in Pharmacology 2012, 3:195.
105. Seeman P., Lee T. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
106. Shotbolt P., Stokes P.R., Owens S.F., Toulopoulou T., Picchioni M.M., Bose S.K., et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychological Medicine 2011, 41:2331-2338.
107. 18F]-DOPA PET study. Neuropsychopharmacology 2013, 38:485-491.
108. Stone J.M., Fusar-Poli P. Abnormal thalamic glutamate and liability to psychosis: State or trait marker?. Schizophrenia Research 2009, 115:94-95.
109. Stone J.M., Howes O.D., Egerton A., Kambeitz J., Allen P., Lythgoe D.J., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biological Psychiatry 2010, 68:599-602.
110. Tan H.Y., Callicott J.H., Weinberger D.R. Prefrontal cognitive systems in schizophrenia: Towards human genetic brain mechanisms. Cognitive Neuropsychiatry 2009, 14:277-298.
111. Taylor S.F., Koeppe R.A., Tandon R., Zubieta J.K., Frey K.A. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 2000, 23:667-675.
112. van Winkel R., Stefanis N.C., Myin-Germeys I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophrenia Bulletin 2008, 34:1095-1105.
113. Villemagne V.L., Wong D.F., Yokoi F., Stephane M., Rice K.C., Matecka D., et al. GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 1999, 33:268-273.
114. Voruganti L.N., Awad A.G. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia-findings from an in vivo SPECT study. Schizophrenia Research 2006, 88:179-186.
115. Widerlov E. A critical appraisal of CSF monoamine metabolite studies in schizophrenia. Annals of the New York Academy of Sciences 1988, 537:309-323.
116. Wise R.A. Dopamine, learning and motivation. Nature Reviews Neuroscience 2004, 5:483-494.
117. Wood S.J., Yucel M., Velakoulis D., Phillips L.J., Yung A.R., Brewer W., et al. Hippocampal and anterior cingulate morphology in subjects at ultra-high-risk for psychosis: The role of family history of psychotic illness. Schizophrenia Research 2005, 75:295-301.
118. Yatham L.N., Liddle P.F., Shiah I.S., Lam R.W., Ngan E., Scarrow G., et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: Effects of treatment with divalproex sodium. The American Journal of Psychiatry 2002, 159:768-774.
119. Yucel M., Wood S.J., Phillips L.J., Stuart G.W., Smith D.J., Yung A., et al. Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. The British Journal of Psychiatry 2003, 182:518-524.
120. Yung A.R., Fusar-Poli P., Nelson B. The ultra high risk approach to define psychosis risk. Current Pharmaceutical Design 2012, 18:346-350.
121. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophrenia Research 2003, 60:21-32.
122. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., et al. Mapping the onset of psychosis: The comprehensive assessment of at-risk mental states. The Australian and New Zealand Journal of Psychiatry 2005, 39:964-971.